Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead

NCT07273656 | Not Yet Recruiting Phase 3

• 1 other identifier: 2023_0127
• Study Type: interventional
• Target: 59
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of the study is to evaluate the efficacy and safety of a combined approach of cryotherapy and tirbanibulin for the treatment of actinic keratosis of the scalp and forehead, repeated every 4 months. A higher rate of complete response is expected with this combination compared to cryotherapy alone, as well as a better response with repeated treatment cycles.

Conditions

Actinic Keratoses; Keratosis

Keywords

Tirbanibulin; Cryotherapy; Squamus cell carcinoma; Skin carcinoma; Actinic Keratosis; Field cancerization

Outcome Measures

Primary Outcomes (1)

• Complete clearance of actinic keratosis

  Complete clearance rate of actinic keratoses at 8 months. A complete response corresponds to the absence of clinically detectable actinic keratosis in the treated area.

  8 months

Secondary Outcomes (5)

• To determine the 12-month effectiveness of a combined approach using cryotherapy and tirbanibulin.

  12 months

• To evaluate the reduction in the number of actinic keratoses after 2 treatment cycles.

  8 months

• To evaluate the reduction in the number of actinic keratoses after 3 treatment cycles.

  12 months

• To evaluate the reduction in the need for cryotherapy with tirbanibulin.

  12 months

• To describe the safety and tolerability by treated side at each follow-up visit.

  12 months

Study Arms (2)

Experimental group

EXPERIMENTAL

Cryotherapy + Tirbanibulin : Tirbanibulin ointment applied once daily for 5 days, repeated 3 times (every 4 months)

Drug: Cryotherapy + Tirbanibulin

Control group

PLACEBO COMPARATOR

Cryotherapy + placebo : Tirbanibulin ointment applied once daily for 5 days, repeated 3 times (every 4 months)

Drug: Cryotherapy + Tirbanibulin

Interventions

Cryotherapy + Tirbanibulin DRUG

Tirbanibulin ointment applied once daily for 5 days, repeated 3 times (every 4 months)

Also known as: Cryotherapy + placebo

Control group; Experimental group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject over 18 years old presenting with ≥ 8 typical actinic keratoses (AK), clinically visible or palpable, grade I or II, with at least 4 AK per hemiscalp,
• Participants who, in the investigator's judgment, are in good general condition (ECOG ≤ 2),
• The AK must be distributed in 2 non-overlapping areas, and of similar grades,
• Patient capable of understanding and adhering to the study visit schedule and other protocol requirements,
• Patient capable of understanding and voluntarily signing informed consent,
• Patient covered by social insurance,
• Patient willing to comply with all study procedures and duration,
• Women of childbearing potential must:
• Have a negative pregnancy test at screening and during the treatment period,
• Use an effective contraceptive method throughout the study participation. Menopausal women (absence of menstruation for at least one year without other medical cause) or surgically sterile women (tubal ligation, hysterectomy, or bilateral oophorectomy) may be enrolled.

You may not qualify if:

• Clinically atypical and/or rapidly evolving actinic keratoses (AK) in the treatment area, and grade 3 AK according to Olsen classification,
• A defined treatment area that would be:
• Located somewhere other than the scalp and/or forehead,
• Within 5 cm of a wound that is not fully healed or a lesion suspicious for carcinoma,
• Prior treatment with tirbanibulin,
• Treatment with 5-fluorouracil (5-FU), imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for actinic keratoses in the treatment area or within 2 cm around this area within 6 weeks prior to the screening visit,
• Use of the following therapies within 2 weeks prior to the screening visit:
• Therapeutic or cosmetic procedures (e.g., liquid nitrogen application, surgical excision, dermabrasion, medium or deep chemical peeling, laser resurfacing) in the treatment area or within 2 cm around the selected treatment area,
• Therapeutic products containing acids (e.g., salicylic acid, fruit acids), topical retinoids, or light peels in the treatment area or within 2 cm around the selected treatment area,
• Allergy to tirbanibulin or any of its components.
• Any condition causing a risk of poor compliance,
• Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign the consent form,
• Women of childbearing potential who refuse to use an effective contraceptive method,
• Pregnant women, women planning to become pregnant, and breastfeeding women,
• Persons deprived of liberty by judicial or administrative decision.

Sponsors & Collaborators

• University Hospital, Lille: lead
• Almirall, SAS: collaborator

MeSH Terms

Conditions

Keratosis; Keratosis, Actinic

Interventions

Cryotherapy; tirbanibulin

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases; Precancerous Conditions; Neoplasms

Intervention Hierarchy (Ancestors)

Therapeutics

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: One single group, each patient serving as their own control, with an intra-individual comparison of one hemiscalp with the contralateral hemiscalp
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: One single group, each patient serving as their own control, with an intra-individual comparison of one hemiscalp with the contralateral hemiscalp

Study Record Dates

• First Submitted: September 23, 2025
• First Posted: December 9, 2025
• Study Start: November 30, 2025
• Primary Completion (Estimated): November 30, 2027
• Study Completion (Estimated): November 30, 2027
• Last Updated: December 9, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share